The U.S. Justice Department moved cannabis to Schedule 3 of the Controlled Substances Act - but drew a sharp line that the industry did not expect. Only FDA-approved drug products containing cannabis, and marijuana produced under a state-issued medical license, received the reclassification. Everything else - unlicensed bulk marijuana, and the far larger state-legal adult-use market - remains in Schedule 1, exactly where it has been for decades. The consequences are immediate, uneven, and nowhere near settled.
A Partial Rescheduling That Creates Two Classes of Cannabis Law
The DOJ's order doesn't just create winners and losers within the cannabis industry. It creates a structural contradiction. The same substance is now, under federal law, simultaneously a Schedule 1 controlled substance and a Schedule 3 controlled substance - depending entirely on the license held by the operator selling it and the approval status of the product being sold.
That split will not survive unchallenged. Opponents of rescheduling will attack the DOJ's authority to implement a partial, channel-specific reclassification using the procedural mechanism it invoked. Cannabis industry stakeholders - particularly those operating in adult-use markets - will argue that a substance cannot rationally occupy two scheduling tiers at once. The DOJ appears to have anticipated this: the order itself contains severability language, signaling that the administration expects parts of it to be struck down in litigation and wants the rest to survive.
The honest read here is that Thursday's action is the beginning of a legal fight, not the end of one.
Section 280E Still Applies - and the Tax Exposure Is Staggering
For the cannabis industry, the most consequential question was never purely philosophical. It was financial. Section 280E of the Internal Revenue Code bars businesses that traffic in Schedule 1 or Schedule 2 controlled substances from deducting ordinary business expenses - though cost of goods sold remains permitted. The result is an effective tax rate that bears no relationship to actual profitability. Many cannabis operators owe taxes that exceed their earnings.
The DOJ's order explicitly leaves adult-use commerce in Schedule 1, which means 280E stays in force for the largest segment of the legal cannabis market. Even for state-licensed medical operators who now fall under Schedule 3, the order states they should no longer be subject to 280E - but "should" and "will" are different words when federal courts are involved, and that position will face immediate challenge.
The numbers at stake for large multi-state operators are not abstract. Recent filings from major publicly traded cannabis companies reveal the scale of accumulated federal tax liability: Trulieve Cannabis carries $630.3 million in federal income tax owed; Curaleaf Holdings, $531.5 million; Verano Holdings, $378.3 million; Cresco Labs, $171.4 million. These figures are not projections. They reflect what these companies owe if 280E is enforced as written - and for much of their business, it still is.
The strategic incentive to fight is obvious. For companies carrying that kind of liability, restructuring or insolvency proceedings become real possibilities if enforcement accelerates. That pressure shapes every legal position they take.
The Tax Court Fight and the Penalty Problem
The case most cannabis tax watchers have been tracking is New Mexico Top Organics v. Commissioner, currently before the U.S. Tax Court. The taxpayer has advanced several arguments for why Section 280E shouldn't apply - arguments that larger operators with far more at stake have been watching closely. Last month, the IRS filed its answering brief, the first time the government has responded in writing to the core taxpayer arguments. The IRS's position, by most readings, leaves cannabis operators facing long odds.
Here's the catch that makes this worse: beyond losing on the substantive 280E question, cannabis taxpayers also risk a 20% substantial understatement penalty under IRC Section 6662. The IRS appears inclined to pursue it. To avoid that penalty, a taxpayer must demonstrate reasonable basis for their filing position - a standard Treasury regulations describe as "significantly higher than not frivolous or not patently improper." A position that is merely arguable doesn't satisfy it.
Large multi-state operators with sophisticated in-house legal and compliance teams face a particular credibility problem on this point. It will be difficult - not impossible, but genuinely difficult - to argue they acted in good faith without knowledge of the risk when their own counsel presumably tracked every development in the rescheduling debate.
One argument circulating in the industry rests on statutory language: a parenthetical "within the meaning of" in Section 280E, which some legal opinions have used to suggest that the IRS, rather than the Tax Court or the Attorney General, determines what counts as a controlled substance for tax purposes. That reading has significant problems. Scheduling authority under the Controlled Substances Act belongs to the Attorney General. No tax opinion changes that allocation of authority, and a court is unlikely to pretend otherwise.
What Operators Should Actually Do Now
Thursday's action does move something. State-licensed medical operators have a credible argument - rooted in the DOJ's own order - that they no longer face 280E liability going forward. That matters. It doesn't resolve prior-year returns, and it doesn't help the adult-use market, but it is not nothing.
For everyone else, the practical calculus hasn't shifted as much as the headlines might suggest. Adult-use operators remain Schedule 1 traffickers under federal law. Their 280E exposure is unchanged. Legal opinions premised on the optimistic view that rescheduling would sweep broadly have not aged well, and operators relying on those opinions for penalty protection should consult counsel about where they actually stand - particularly if they have already filed returns taking aggressive 280E positions.
Policy momentum is real. The direction of travel - toward some form of federal normalization of cannabis - is visible to anyone paying attention. But courts don't rule on momentum. They rule on statutes, and the statute still says what it says for most of the industry. Until Congress amends Section 280E directly, or until a comprehensive rescheduling of all cannabis clears the full CSA process, the IRS will enforce the law as written. Optimism is not a defense in Tax Court.
